The author of a new guidebook on GLP-1s and other experts share their tips for how clinicians can optimize patient success ...

Eli Lilly and Company discovers ... and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including ...

but taking into account the huge need there would probably continue to be supply constraints until we had an oral medicine with an injectable-like efficacy,” President of Lilly Diabetes and ...

Shares of Eli Lilly & Co. were headed for their worst ... citing slower-than-expected growth in sales of its diabetes and weight-loss drugs. “While the U.S. incretin market grew 45% compared ...

Eli Lilly’s expectations for sales in the fourth quarter of last year missed forecasts, driven by lower-than-expected sales of its diabetes and obesity drugs Mounjaro and Zepbound. This is ...

2024 revenue forecast: $45.0 billion (+32% YoY), below the $45.50 billion consensus. 2025 revenue guidance: $58.0 billion to $61.0 billion, driven by new medicines and global expansions.

Eli Lilly Cuts Q4 Revenue Guidance, Expects Around $5.5 Billion Sales From Weight Loss/Diabetes Drugs, Stock Tanks Vandana Singh Tue, Jan 14, 2025, 10:11 AM 2 min read ...

Lilly yesterday announced the next component in the ‘beyond the pill’ strategy it is constructing for diabetes, a new alliance with digital health company Rimidi.

Eli Lilly has revised its revenue forecast for 2024 after seeing weaker-than-expected growth for its diabetes and obesity therapies – but still said sales rose around a third over the prior year.

Eli Lilly (LLY) is set to announce Q4 earnings results, with analysts expecting positive growth driven by key drugs and new product launches.

SAN FRANCISCO — Eli Lilly said Monday it would acquire a cancer program from startup Scorpion Therapeutics in a deal worth up to $2.5 billion, as the Indianapolis company broadens its pipeline.

alleging that the companies manipulated the prices of insulin and other diabetes medications. The FCPS lawsuit alleges that pharmaceutical companies Eli Lilly, Sanofi, and Novo Nordisk and ...